Share Price and Basic Stock Data
Last Updated: October 10, 2025, 9:43 pm
| PEG Ratio | 0.23 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Indraprastha Medical Corporation Ltd, a prominent player in the Hospitals & Medical Services industry, has a market capitalization of ₹5,258 Cr. The company’s price stands at ₹574 with a P/E ratio of 31.4. In the last quarter, the company reported a net profit of ₹161 Cr. with an operating profit margin (OPM) of 20%. The company has shown steady revenue growth over the past few quarters, indicating a strong market presence and effective sales strategies. Despite facing challenges in managing expenses, the company has been able to maintain a healthy operating profit pattern over time.
Profitability and Efficiency Metrics
With a Return on Equity (ROE) of 30.0% and Return on Capital Employed (ROCE) of 39.1%, Indraprastha Medical Corporation Ltd demonstrates robust profitability. The Interest Coverage Ratio (ICR) of 51.79x reflects the company’s ability to meet interest obligations comfortably. However, the Cash Conversion Cycle (CCC) of 20 days indicates room for improvement in managing working capital efficiently. The company’s margins and returns outperform typical sector ranges, showcasing operational efficiency and effective capital utilization.
Balance Sheet Strength and Financial Ratios
The company holds reserves worth ₹505 Cr. and has borrowings amounting to ₹33 Cr. The Price-to-Book Value (P/BV) ratio of 3.30x suggests the stock is trading at a premium compared to its book value. Indraprastha Medical Corporation Ltd maintains a healthy liquidity position with a Current Ratio above industry standards. While the debt-equity ratio indicates moderate leverage, the company’s interest coverage and working capital health point towards a strong balance sheet and financial stability.
Shareholding Pattern and Investor Confidence
Promoters hold a significant stake of 51.00% in the company, ensuring stability and long-term vision. Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) hold 2.73% and 3.56%, respectively, reflecting moderate institutional interest. Public shareholding stands at 42.74%, indicating retail investor participation. Changes in shareholding patterns can influence market perception and valuation, with higher promoter holding typically viewed positively by investors.
Outlook, Risks, and Final Insight
Looking ahead, Indraprastha Medical Corporation Ltd’s growth prospects remain promising, driven by increasing healthcare demand and expansion opportunities. However, regulatory changes and intense market competition pose significant risks to the company’s performance. Strengthening operational efficiency, enhancing working capital management, and diversifying revenue streams could bolster future growth. In conclusion, while the company exhibits strong financial metrics and market confidence, mitigating risks and focusing on sustainable growth strategies will be crucial for long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Indraprastha Medical Corporation Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 48.1 Cr. | 144 | 195/140 | 6.47 | 115 | 2.44 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 24.0 Cr. | 22.9 | 38.0/0.00 | 25.5 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 13.4 Cr. | 13.0 | 23.4/12.1 | 149 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 128 Cr. | 68.2 | 98.7/51.0 | 27.7 | 16.1 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 25.3 Cr. | 4.69 | 7.90/3.40 | 0.86 | 2.49 | 0.00 % | 79.2 % | 85.5 % | 10.0 |
| Industry Average | 28,764.07 Cr | 849.85 | 66.27 | 95.05 | 0.31% | 15.48% | 14.81% | 9.04 |
All Competitor Stocks of Indraprastha Medical Corporation Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 263 | 284 | 277 | 274 | 307 | 317 | 306 | 315 | 348 | 350 | 325 | 334 | 365 |
| Expenses | 226 | 241 | 240 | 241 | 259 | 267 | 259 | 266 | 281 | 286 | 273 | 272 | 292 |
| Operating Profit | 37 | 44 | 37 | 33 | 47 | 50 | 47 | 48 | 67 | 64 | 52 | 61 | 73 |
| OPM % | 14% | 15% | 13% | 12% | 15% | 16% | 15% | 15% | 19% | 18% | 16% | 18% | 20% |
| Other Income | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 5 | 6 | 5 | 6 | 7 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 |
| Depreciation | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 10 |
| Profit before tax | 27 | 34 | 29 | 27 | 40 | 44 | 41 | 42 | 60 | 57 | 45 | 55 | 68 |
| Tax % | 24% | 26% | 29% | 27% | 24% | 25% | 28% | 25% | 25% | 26% | 26% | 26% | 25% |
| Net Profit | 20 | 25 | 21 | 20 | 30 | 33 | 29 | 31 | 45 | 42 | 33 | 41 | 51 |
| EPS in Rs | 2.21 | 2.74 | 2.28 | 2.16 | 3.33 | 3.58 | 3.21 | 3.40 | 4.88 | 4.63 | 3.58 | 4.47 | 5.61 |
Last Updated: August 20, 2025, 9:05 am
Below is a detailed analysis of the quarterly data for Indraprastha Medical Corporation Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 365.00 Cr.. The value appears strong and on an upward trend. It has increased from 334.00 Cr. (Mar 2025) to 365.00 Cr., marking an increase of 31.00 Cr..
- For Expenses, as of Jun 2025, the value is 292.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 272.00 Cr. (Mar 2025) to 292.00 Cr., marking an increase of 20.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 73.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Mar 2025) to 73.00 Cr., marking an increase of 12.00 Cr..
- For OPM %, as of Jun 2025, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Mar 2025) to 20.00%, marking an increase of 2.00%.
- For Other Income, as of Jun 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 10.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.00 Cr. (Mar 2025) to 10.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 55.00 Cr. (Mar 2025) to 68.00 Cr., marking an increase of 13.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to 25.00%, marking a decrease of 1.00%.
- For Net Profit, as of Jun 2025, the value is 51.00 Cr.. The value appears strong and on an upward trend. It has increased from 41.00 Cr. (Mar 2025) to 51.00 Cr., marking an increase of 10.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.61. The value appears strong and on an upward trend. It has increased from 4.47 (Mar 2025) to 5.61, marking an increase of 1.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 5:11 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 678 | 714 | 755 | 766 | 753 | 788 | 831 | 613 | 888 | 1,099 | 1,245 | 1,356 |
| Expenses | 587 | 630 | 675 | 686 | 678 | 706 | 743 | 572 | 768 | 947 | 1,050 | 1,112 |
| Operating Profit | 91 | 85 | 80 | 79 | 74 | 82 | 87 | 41 | 120 | 152 | 195 | 244 |
| OPM % | 13% | 12% | 11% | 10% | 10% | 10% | 11% | 7% | 14% | 14% | 16% | 18% |
| Other Income | 1 | 1 | 1 | -0 | -1 | -1 | -0 | -0 | -3 | 9 | 16 | 23 |
| Interest | 10 | 8 | 7 | 8 | 9 | 7 | 6 | 3 | 3 | 4 | 4 | 6 |
| Depreciation | 28 | 28 | 35 | 31 | 31 | 30 | 33 | 33 | 35 | 39 | 40 | 44 |
| Profit before tax | 54 | 50 | 39 | 41 | 34 | 45 | 48 | 4 | 79 | 117 | 166 | 216 |
| Tax % | 35% | 34% | 37% | 36% | 38% | 36% | 9% | 46% | 26% | 26% | 25% | 26% |
| Net Profit | 35 | 32 | 24 | 26 | 21 | 28 | 44 | 2 | 59 | 86 | 124 | 161 |
| EPS in Rs | 3.87 | 3.54 | 2.66 | 2.86 | 2.30 | 3.10 | 4.76 | 0.25 | 6.39 | 9.40 | 13.52 | 17.56 |
| Dividend Payout % | 47% | 51% | 68% | 63% | 65% | 52% | 0% | 0% | 39% | 32% | 33% | 26% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -8.57% | -25.00% | 8.33% | -19.23% | 33.33% | 57.14% | -95.45% | 2850.00% | 45.76% | 44.19% | 29.84% |
| Change in YoY Net Profit Growth (%) | 0.00% | -16.43% | 33.33% | -27.56% | 52.56% | 23.81% | -152.60% | 2945.45% | -2804.24% | -1.58% | -14.35% |
Indraprastha Medical Corporation Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 10% |
| 3 Years: | 15% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 29% |
| 3 Years: | 37% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 58% |
| 3 Years: | 89% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 23% |
| 3 Years: | 28% |
| Last Year: | 30% |
Last Updated: September 5, 2025, 7:30 am
Balance Sheet
Last Updated: June 16, 2025, 11:57 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 |
| Reserves | 95 | 103 | 132 | 139 | 141 | 152 | 176 | 181 | 234 | 288 | 386 | 505 |
| Borrowings | 63 | 50 | 52 | 67 | 66 | 21 | 4 | 3 | 5 | 2 | 34 | 33 |
| Other Liabilities | 199 | 196 | 185 | 160 | 134 | 157 | 177 | 157 | 131 | 173 | 212 | 222 |
| Total Liabilities | 449 | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 555 | 723 | 852 |
| Fixed Assets | 293 | 286 | 301 | 296 | 294 | 280 | 303 | 283 | 277 | 275 | 347 | 328 |
| CWIP | 2 | 3 | 3 | 0 | 0 | 1 | 0 | 3 | 0 | 3 | 0 | 33 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 154 | 153 | 157 | 163 | 138 | 141 | 146 | 145 | 185 | 278 | 376 | 491 |
| Total Assets | 449 | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 555 | 723 | 852 |
Below is a detailed analysis of the balance sheet data for Indraprastha Medical Corporation Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 92.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 92.00 Cr..
- For Reserves, as of Mar 2025, the value is 505.00 Cr.. The value appears strong and on an upward trend. It has increased from 386.00 Cr. (Mar 2024) to 505.00 Cr., marking an increase of 119.00 Cr..
- For Borrowings, as of Mar 2025, the value is 33.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 34.00 Cr. (Mar 2024) to 33.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 222.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 212.00 Cr. (Mar 2024) to 222.00 Cr., marking an increase of 10.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 852.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 723.00 Cr. (Mar 2024) to 852.00 Cr., marking an increase of 129.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 328.00 Cr.. The value appears to be declining and may need further review. It has decreased from 347.00 Cr. (Mar 2024) to 328.00 Cr., marking a decrease of 19.00 Cr..
- For CWIP, as of Mar 2025, the value is 33.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 33.00 Cr., marking an increase of 33.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 491.00 Cr.. The value appears strong and on an upward trend. It has increased from 376.00 Cr. (Mar 2024) to 491.00 Cr., marking an increase of 115.00 Cr..
- For Total Assets, as of Mar 2025, the value is 852.00 Cr.. The value appears strong and on an upward trend. It has increased from 723.00 Cr. (Mar 2024) to 852.00 Cr., marking an increase of 129.00 Cr..
Notably, the Reserves (505.00 Cr.) exceed the Borrowings (33.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 28.00 | 35.00 | 28.00 | 12.00 | 8.00 | 61.00 | 83.00 | 38.00 | 115.00 | 150.00 | 161.00 | 211.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 40 | 41 | 47 | 41 | 35 | 35 | 40 | 18 | 23 | 17 | 20 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 35 | 40 | 41 | 47 | 41 | 35 | 35 | 40 | 18 | 23 | 17 | 20 |
| Working Capital Days | -27 | -35 | -22 | -17 | -7 | -5 | -10 | -1 | -2 | -12 | -24 | -19 |
| ROCE % | 26% | 23% | 18% | 17% | 15% | 19% | 21% | 3% | 29% | 34% | 38% | 39% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 384 | 0.08 | 0.01 | 384 | 2025-04-22 17:25:31 | 0% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 13.52 | 9.40 | 6.39 | 0.25 | 4.76 |
| Diluted EPS (Rs.) | 13.52 | 9.40 | 6.39 | 0.25 | 4.76 |
| Cash EPS (Rs.) | 17.89 | 13.68 | 10.21 | 3.89 | 8.36 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 52.12 | 41.39 | 35.50 | 29.75 | 29.21 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 52.12 | 41.39 | 35.50 | 29.75 | 29.21 |
| Dividend / Share (Rs.) | 4.50 | 3.00 | 2.50 | 0.00 | 0.00 |
| Revenue From Operations / Share (Rs.) | 135.78 | 119.85 | 96.89 | 66.91 | 90.62 |
| PBDIT / Share (Rs.) | 22.93 | 17.53 | 12.81 | 4.47 | 9.50 |
| PBIT / Share (Rs.) | 18.56 | 13.25 | 9.00 | 0.83 | 5.90 |
| PBT / Share (Rs.) | 18.12 | 12.78 | 8.63 | 0.46 | 5.26 |
| Net Profit / Share (Rs.) | 13.52 | 9.40 | 6.39 | 0.25 | 4.76 |
| PBDIT Margin (%) | 16.89 | 14.62 | 13.22 | 6.67 | 10.48 |
| PBIT Margin (%) | 13.67 | 11.05 | 9.28 | 1.24 | 6.51 |
| PBT Margin (%) | 13.34 | 10.66 | 8.90 | 0.69 | 5.80 |
| Net Profit Margin (%) | 9.95 | 7.84 | 6.60 | 0.37 | 5.25 |
| Return on Networth / Equity (%) | 25.94 | 22.70 | 18.01 | 0.85 | 16.28 |
| Return on Capital Employeed (%) | 30.50 | 28.54 | 22.40 | 2.41 | 17.48 |
| Return On Assets (%) | 17.13 | 15.51 | 12.69 | 0.53 | 9.71 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Asset Turnover Ratio (%) | 1.95 | 2.16 | 1.99 | 1.39 | 1.91 |
| Current Ratio (X) | 1.86 | 1.72 | 1.68 | 1.22 | 1.01 |
| Quick Ratio (X) | 1.82 | 1.66 | 1.58 | 1.14 | 0.92 |
| Inventory Turnover Ratio (X) | 0.00 | 21.00 | 18.55 | 10.95 | 14.88 |
| Dividend Payout Ratio (NP) (%) | 22.18 | 26.60 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 16.76 | 18.27 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 77.82 | 73.40 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 83.24 | 81.73 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 51.79 | 37.55 | 34.43 | 12.27 | 14.72 |
| Interest Coverage Ratio (Post Tax) (X) | 31.53 | 21.13 | 18.19 | 1.70 | 8.37 |
| Enterprise Value (Cr.) | 1350.00 | 583.80 | 467.36 | 465.22 | 291.19 |
| EV / Net Operating Revenue (X) | 1.08 | 0.53 | 0.52 | 0.75 | 0.35 |
| EV / EBITDA (X) | 6.42 | 3.63 | 3.98 | 11.36 | 3.34 |
| MarketCap / Net Operating Revenue (X) | 1.26 | 0.64 | 0.60 | 0.80 | 0.37 |
| Retention Ratios (%) | 77.81 | 73.39 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 3.30 | 1.88 | 1.65 | 1.81 | 1.16 |
| Price / Net Operating Revenue (X) | 1.26 | 0.64 | 0.60 | 0.80 | 0.37 |
| EarningsYield | 0.07 | 0.12 | 0.10 | 0.00 | 0.14 |
After reviewing the key financial ratios for Indraprastha Medical Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 13.52. This value is within the healthy range. It has increased from 9.40 (Mar 23) to 13.52, marking an increase of 4.12.
- For Diluted EPS (Rs.), as of Mar 24, the value is 13.52. This value is within the healthy range. It has increased from 9.40 (Mar 23) to 13.52, marking an increase of 4.12.
- For Cash EPS (Rs.), as of Mar 24, the value is 17.89. This value is within the healthy range. It has increased from 13.68 (Mar 23) to 17.89, marking an increase of 4.21.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 52.12. It has increased from 41.39 (Mar 23) to 52.12, marking an increase of 10.73.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 52.12. It has increased from 41.39 (Mar 23) to 52.12, marking an increase of 10.73.
- For Dividend / Share (Rs.), as of Mar 24, the value is 4.50. This value exceeds the healthy maximum of 3. It has increased from 3.00 (Mar 23) to 4.50, marking an increase of 1.50.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 135.78. It has increased from 119.85 (Mar 23) to 135.78, marking an increase of 15.93.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 22.93. This value is within the healthy range. It has increased from 17.53 (Mar 23) to 22.93, marking an increase of 5.40.
- For PBIT / Share (Rs.), as of Mar 24, the value is 18.56. This value is within the healthy range. It has increased from 13.25 (Mar 23) to 18.56, marking an increase of 5.31.
- For PBT / Share (Rs.), as of Mar 24, the value is 18.12. This value is within the healthy range. It has increased from 12.78 (Mar 23) to 18.12, marking an increase of 5.34.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 13.52. This value is within the healthy range. It has increased from 9.40 (Mar 23) to 13.52, marking an increase of 4.12.
- For PBDIT Margin (%), as of Mar 24, the value is 16.89. This value is within the healthy range. It has increased from 14.62 (Mar 23) to 16.89, marking an increase of 2.27.
- For PBIT Margin (%), as of Mar 24, the value is 13.67. This value is within the healthy range. It has increased from 11.05 (Mar 23) to 13.67, marking an increase of 2.62.
- For PBT Margin (%), as of Mar 24, the value is 13.34. This value is within the healthy range. It has increased from 10.66 (Mar 23) to 13.34, marking an increase of 2.68.
- For Net Profit Margin (%), as of Mar 24, the value is 9.95. This value is within the healthy range. It has increased from 7.84 (Mar 23) to 9.95, marking an increase of 2.11.
- For Return on Networth / Equity (%), as of Mar 24, the value is 25.94. This value is within the healthy range. It has increased from 22.70 (Mar 23) to 25.94, marking an increase of 3.24.
- For Return on Capital Employeed (%), as of Mar 24, the value is 30.50. This value is within the healthy range. It has increased from 28.54 (Mar 23) to 30.50, marking an increase of 1.96.
- For Return On Assets (%), as of Mar 24, the value is 17.13. This value is within the healthy range. It has increased from 15.51 (Mar 23) to 17.13, marking an increase of 1.62.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 1.95. It has decreased from 2.16 (Mar 23) to 1.95, marking a decrease of 0.21.
- For Current Ratio (X), as of Mar 24, the value is 1.86. This value is within the healthy range. It has increased from 1.72 (Mar 23) to 1.86, marking an increase of 0.14.
- For Quick Ratio (X), as of Mar 24, the value is 1.82. This value is within the healthy range. It has increased from 1.66 (Mar 23) to 1.82, marking an increase of 0.16.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 4. It has decreased from 21.00 (Mar 23) to 0.00, marking a decrease of 21.00.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 22.18. This value is within the healthy range. It has decreased from 26.60 (Mar 23) to 22.18, marking a decrease of 4.42.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 16.76. This value is below the healthy minimum of 20. It has decreased from 18.27 (Mar 23) to 16.76, marking a decrease of 1.51.
- For Earning Retention Ratio (%), as of Mar 24, the value is 77.82. This value exceeds the healthy maximum of 70. It has increased from 73.40 (Mar 23) to 77.82, marking an increase of 4.42.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 83.24. This value exceeds the healthy maximum of 70. It has increased from 81.73 (Mar 23) to 83.24, marking an increase of 1.51.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 51.79. This value is within the healthy range. It has increased from 37.55 (Mar 23) to 51.79, marking an increase of 14.24.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 31.53. This value is within the healthy range. It has increased from 21.13 (Mar 23) to 31.53, marking an increase of 10.40.
- For Enterprise Value (Cr.), as of Mar 24, the value is 1,350.00. It has increased from 583.80 (Mar 23) to 1,350.00, marking an increase of 766.20.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.08. This value is within the healthy range. It has increased from 0.53 (Mar 23) to 1.08, marking an increase of 0.55.
- For EV / EBITDA (X), as of Mar 24, the value is 6.42. This value is within the healthy range. It has increased from 3.63 (Mar 23) to 6.42, marking an increase of 2.79.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.26. This value is within the healthy range. It has increased from 0.64 (Mar 23) to 1.26, marking an increase of 0.62.
- For Retention Ratios (%), as of Mar 24, the value is 77.81. This value exceeds the healthy maximum of 70. It has increased from 73.39 (Mar 23) to 77.81, marking an increase of 4.42.
- For Price / BV (X), as of Mar 24, the value is 3.30. This value exceeds the healthy maximum of 3. It has increased from 1.88 (Mar 23) to 3.30, marking an increase of 1.42.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.26. This value is within the healthy range. It has increased from 0.64 (Mar 23) to 1.26, marking an increase of 0.62.
- For EarningsYield, as of Mar 24, the value is 0.07. This value is below the healthy minimum of 5. It has decreased from 0.12 (Mar 23) to 0.07, marking a decrease of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Indraprastha Medical Corporation Ltd:
- Net Profit Margin: 9.95%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 30.5% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 25.94% (Industry Average ROE: 14.16%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 31.53
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.82
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 31 (Industry average Stock P/E: 54.74)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.95%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Sarita Vihar, New Delhi Delhi 110076 | imclshares@apollohospitals.com http://www.apollohospitals.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Prathap C Reddy | Vice Chairman |
| Mr. Shivakumar Pattabhiraman | Managing Director |
| Mr. Sudhir Jalan | Director |
| Prof. (Dr) Mahesh Verma | Director |
| Mr. Salil Singhal | Director |
| Dr.(Ms.) Suneeta Reddy | Director |
| Mr. Vinayak Chatterjee | Director |
| Ms. Vineeta Rai | Director |
| Mr. Sandip Somany | Director |
| Mr. Tejpreet Singh Chopra | Director |
| Ms. Madhumita Ganguli | Director |
| Dr.(Ms.) Sangita Reddy | Director |
FAQ
What is the intrinsic value of Indraprastha Medical Corporation Ltd?
Indraprastha Medical Corporation Ltd's intrinsic value (as of 10 October 2025) is 488.17 which is 13.90% lower the current market price of 567.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹5,207 Cr. market cap, FY2025-2026 high/low of 626/307, reserves of ₹505 Cr, and liabilities of 852 Cr.
What is the Market Cap of Indraprastha Medical Corporation Ltd?
The Market Cap of Indraprastha Medical Corporation Ltd is 5,207 Cr..
What is the current Stock Price of Indraprastha Medical Corporation Ltd as on 10 October 2025?
The current stock price of Indraprastha Medical Corporation Ltd as on 10 October 2025 is 567.
What is the High / Low of Indraprastha Medical Corporation Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Indraprastha Medical Corporation Ltd stocks is 626/307.
What is the Stock P/E of Indraprastha Medical Corporation Ltd?
The Stock P/E of Indraprastha Medical Corporation Ltd is 31.0.
What is the Book Value of Indraprastha Medical Corporation Ltd?
The Book Value of Indraprastha Medical Corporation Ltd is 65.1.
What is the Dividend Yield of Indraprastha Medical Corporation Ltd?
The Dividend Yield of Indraprastha Medical Corporation Ltd is 0.79 %.
What is the ROCE of Indraprastha Medical Corporation Ltd?
The ROCE of Indraprastha Medical Corporation Ltd is 39.1 %.
What is the ROE of Indraprastha Medical Corporation Ltd?
The ROE of Indraprastha Medical Corporation Ltd is 30.0 %.
What is the Face Value of Indraprastha Medical Corporation Ltd?
The Face Value of Indraprastha Medical Corporation Ltd is 10.0.